Experienced in Peripheral Neuropathy

Wen-chan C. Chiu

No. 123, Ta Pei Road, 833, 
Kaohsiung, KHQ, TW 
Experienced in Peripheral Neuropathy
No. 123, Ta Pei Road, 833, 
Kaohsiung, KHQ, TW 
OverviewLocationsClinical Research

Overview

Wen-chan Chiu practices in Kaohsiung, Taiwan. Chiu is rated as an Experienced expert by MediFind in the treatment of Peripheral Neuropathy. Their top areas of expertise are Autonomic Neuropathy, Sensorimotor Polyneuropathy, Diabetic Neuropathy, and Type 2 Diabetes (T2D).

Their clinical research consists of co-authoring 59 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Peripheral Neuropathy.

Locations

No. 123, Ta Pei Road, 833, Kaohsiung, KHQ, Taiwan
Other Locations
Cardinal Tien Hospital Yung Ho Branch
Yungho, TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: April 23, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 2 Less Clinical Trials

59 Total Publications

Impact of Risk Factors and a New Transfer Pathway on Endovascular Thrombectomy Outcomes in Acute Ischemic Stroke.
Impact of Risk Factors and a New Transfer Pathway on Endovascular Thrombectomy Outcomes in Acute Ischemic Stroke.
Journal: World neurosurgery
Published: August 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chiu's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile